title: Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
abstract: Substantial advances have been made in understanding critical molecular and cellular mechanisms driving tumor initiation, maintenance, and progression in non-small-cell lung cancer (NSCLC). Over the last decade, these findings have led to the discovery of a variety of novel drug targets and the development of new treatment strategies. Already, the standard of care for patients with advanced-stage NSCLC is shifting from selecting therapy empirically based on a patient's clinicopathologic features to using biomarker-driven treatment algorithms based on the molecular profile of a patient's tumor. This approach is currently best exemplified by treating patients with NSCLC with first-line tyrosine kinase inhibitors when their cancers harbor gain-of-function hotspot mutations in the epidermal growth factor receptor (EGFR) gene or anaplastic lymphoma kinase (ALK) gene rearrangements. These genotype-based targeted therapies represent the first step toward personalizing NSCLC therapy. Recent technology advances in multiplex genotyping and high-throughput genomic profiling by next-generation sequencing technologies now offer the possibility of rapidly and comprehensively interrogating the cancer genome of individual patients from small tumor biopsies. This advance provides the basis for categorizing molecular-defined subsets of patients with NSCLC in whom a growing list of novel molecularly targeted therapeutics are clinically evaluable and additional novel drug targets can be discovered. Increasingly, practicing oncologists are facing the challenge of determining how to select, interpret, and apply these new genetic and genomic assays. This review summarizes the evolution, early success, current status, challenges, and opportunities for clinical application of genotyping and genomic tests in therapeutic decision making for NSCLC.
authors: University of California Davis Comprehensive Cancer Center, Division of Hematology and Oncology, Sacramento, CA 95817, USA. tianhong.li@ucdmc.ucdavis.edu
authors: Tianhong
authors: T
authors: Li
authors: Hsing-Jien
authors: HJ
authors: Kung
authors: Philip C
authors: PC
authors: Mack
authors: David R
authors: DR
authors: Gandara
mesh_terms: D000465:Algorithms; D014408:Biomarkers, Tumor / Q000235:genetics*; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D004252:DNA Mutational Analysis; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D052138:Genes, Neoplasm / Q000235:genetics; D005820:Genetic Testing / Q000379:methods; D015894:Genome, Human; D005838:Genotype; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology / Q000628:therapy*; D018579:Patient Selection; D057285:Precision Medicine
chemical_list: D014408:Biomarkers, Tumor
references: N Biotechnol. 2012 Sep 15;29(6):651-5
references: 22484859
references: J Clin Oncol. 2005 Sep 1;23(25):5900-9
references: 16043828
references: J Clin Oncol. 2009 Sep 10;27(26):4247-53
references: 19667264
references: Lancet Oncol. 2010 Feb;11(2):121-8
references: 20022809
references: Genome Med. 2010 Nov 26;2(11):84
references: 21114804
references: Sci Transl Med. 2011 Mar 23;3(75):75ra26
references: 21430269
references: N Engl J Med. 2009 Sep 3;361(10):947-57
references: 19692680
references: N Engl J Med. 2005 Jul 14;353(2):123-32
references: 16014882
references: Methods Enzymol. 2011;498:409-26
references: 21601688
references: Clin Cancer Res. 2012 Mar 15;18(6):1555-60
references: 22422408
references: Nucleic Acids Res. 2010 Nov;38(20):6985-96
references: 20587502
references: J Clin Oncol. 2010 Dec 10;28(35):5219-28
references: 20975063
references: Ann Oncol. 2011 Dec;22(12):2616-2624
references: 22071650
references: Cell. 2011 Apr 1;145(1):19-24
references: 21458664
references: Science. 2011 Jul 15;333(6040):348-53
references: 21764749
references: Nature. 2008 Apr 17;452(7189):872-6
references: 18421352
references: Nature. 2010 May 27;465(7297):473-7
references: 20505728
references: Cell. 2011 Mar 4;144(5):646-74
references: 21376230
references: Nature. 2010 Oct 28;467(7319):1061-73
references: 20981092
references: J Natl Compr Canc Netw. 2011 Nov;9 Suppl 5:S1-32; quiz S33
references: 22138009
references: J Clin Oncol. 2012 Mar 10;30(8):863-70
references: 22215748
references: Br J Cancer. 2006 Jan 30;94(2):318-22
references: 16421597
references: N Engl J Med. 2012 Mar 8;366(10):883-892
references: 22397650
references: PLoS Genet. 2011 Sep;7(9):e1002280
references: 21935354
references: Anal Biochem. 2005 Sep 1;344(1):33-42
references: 16039598
references: N Engl J Med. 2010 Jun 24;362(25):2380-8
references: 20573926
references: Lancet Oncol. 2011 Feb;12(2):175-80
references: 21277552
references: N Biotechnol. 2009 Apr;25(4):195-203
references: 19429539
references: J Clin Oncol. 2010 Nov 20;28(33):4877-83
references: 20921468
references: J Clin Invest. 2007 Oct;117(10):2740-50
references: 17909619
references: Clin Lung Cancer. 2009 Nov;10(6):392-4
references: 19900855
references: Nature. 2008 Oct 23;455(7216):1069-75
references: 18948947
references: Clin Lung Cancer. 2012 Sep;13(5):321-5
references: 22677432
references: PLoS Biol. 2007 Sep 4;5(10):e254
references: 17803354
references: Lancet Oncol. 2011 Aug;12(8):735-42
references: 21783417
references: Clin Cancer Res. 2012 Mar 1;18(5):1472-82
references: 22235099
references: Nat Med. 2011 Mar;17(3):297-303
references: 21383744
references: Arch Pathol Lab Med. 2009 May;133(5):743-55
references: 19415949
references: Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
references: 20952405
references: J Clin Oncol. 2010 Nov 1;28(31):4769-77
references: 20921461
references: CA Cancer J Clin. 2012 Jul-Aug;62(4):220-41
references: 22700443
references: Clin Chest Med. 2011 Dec;32(4):703-40
references: 22054881
references: Nat Genet. 2007 Mar;39(3):347-51
references: 17293865
references: Science. 2011 Jul 15;333(6040):307
references: 21700836
references: J Natl Compr Canc Netw. 2022 May;20(5):497-530
references: 35545176
references: Nature. 2010 Jan 14;463(7278):184-90
references: 20016488
references: Nature. 2009 Apr 9;458(7239):719-24
references: 19360079
references: Genes Chromosomes Cancer. 2012 Jan;51(1):54-65
references: 21938754
references: Cancer Discov. 2012 Jan;2(1):82-93
references: 22585170
references: J Natl Compr Canc Netw. 2011 Dec;9 Suppl 6:S1-16
references: 22203777
references: Int J Oncol. 2002 Aug;21(2):369-73
references: 12118333
references: J Clin Oncol. 2008 May 20;26(15):2442-9
references: 18458038
references: J Clin Oncol. 2011 May 20;29(15):2121-7
references: 21482992
references: PLoS One. 2009 Nov 18;4(11):e7887
references: 19924296
references: Cancer Discov. 2011 Jun;1(1):44-53
references: 22586319
references: Sci Transl Med. 2011 Nov 30;3(111):111ra121
references: 22133722
references: J Thorac Oncol. 2012 May;7(5):775-6
references: 22722783
references: Nature. 2008 Oct 23;455(7216):1061-8
references: 18772890
references: EMBO Mol Med. 2010 May;2(5):146-58
references: 20432502
references: Nature. 2004 Oct 21;431(7011):931-45
references: 15496913
references: Nat Biotechnol. 2011 Jul 24;29(8):723-30
references: 21785424
references: N Engl J Med. 2004 May 20;350(21):2129-39
references: 15118073
references: J Mol Diagn. 2011 Jan;13(1):74-84
references: 21227397
references: Nat Rev Genet. 2010 Oct;11(10):685-96
references: 20847746
references: Lancet Oncol. 2012 Mar;13(3):239-46
references: 22285168
references: N Engl J Med. 2010 Oct 28;363(18):1693-703
references: 20979469